Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. (Name of registrant as specified in its charter) | Wisconsin 39-1144397 | | --- | | (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 28, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ until ___ Securities Registered under Section 12(g) of the Act Common Stock, par value $.001 per share Indicate by check mark if the registrant is a well-known seasoned issuer, as defi ...

Financial Performance - Fourth-quarter net sales were $1.07 billion, a decrease of 1% compared to $1.08 billion in the same period of fiscal 2024[2]. - Full-year net sales were $4.51 billion, down 2% from $4.58 billion in fiscal 2024, primarily due to prior year divestitures of non-core assets[2][10]. - Fourth-quarter reported diluted EPS was $0.74, a decrease of 15% from $0.87 in the same period of fiscal 2024; adjusted diluted EPS was $0.91, down 4% from $0.95[3][9]. - Full-year reported diluted EPS was $3.17, down 21% from $4.01 in fiscal 2024; adjusted diluted EPS was $4.20, an increase of 1% from $4.17[3][10]. - Net earnings for the twelve months ended October 31, 2025, were $316.1 million, down from $418.9 million in 2024, representing a decrease of 24.5%[33]. - The company reported a diluted net earnings per share of $3.17 for the twelve months ended October 31, 2025, compared to $4.01 in 2024, a decline of 21.0%[33]. Cash Flow and Shareholder Returns - Record free cash flow of $578 million was generated in fiscal 2025, largely due to working capital improvements[5]. - The company returned $441 million to shareholders through cash dividends and common stock repurchases[5]. - Net cash provided by operating activities increased to $662.0 million for the twelve months ended October 31, 2025, up from $569.9 million in 2024, representing a growth of 16.2%[39]. - Free cash flow for the twelve months ended October 31, 2025, was $578.3 million, an increase of 22.9% from $470.7 million in 2024[43]. Operational Efficiency - Professional segment full-year earnings margin improved to 19.4%, up from 18.0% in the prior year, driven by productivity improvements and net price realization[4][10]. - SG&A expense as a percentage of net sales for fiscal 2025 was 22.5%, compared to 22.2% in fiscal 2024, primarily driven by lower net sales volume and higher incentive expenses[17]. - Gross profit for the twelve months ended October 31, 2025, was $1,504.8 million, resulting in a gross margin of 33.4%, down from 33.8% in 2024[33]. - Adjusted gross profit for the twelve months ended October 31, 2025, was $1,536.4 million, slightly down from $1,555.0 million in 2024, reflecting a decrease of 1.2%[42]. - The adjusted gross margin improved to 34.1% for the twelve months ended October 31, 2025, compared to 33.9% in 2024[42]. - Operating earnings for the twelve months ended October 31, 2025, were $409.9 million, down 23.2% from $533.3 million in 2024[42]. Strategic Initiatives and Future Outlook - Fiscal 2026 adjusted diluted EPS guidance is set between $4.35 and $4.50, reflecting mid-single digit earnings growth expectations[5][7]. - The Tornado Infrastructure Equipment acquisition is expected to contribute approximately 2% to total company net sales and have a modestly accretive impact on adjusted diluted EPS[8]. - The company anticipates that the differences between adjusted diluted EPS for fiscal 2026 and diluted EPS will include non-cash, large, and/or unpredictable charges and benefits[29]. - The company launched the "Amplifying Maximum Productivity" (AMP) initiative in the first quarter of fiscal 2024, which is expected to impact future productivity and operational efficiency[42]. Balance Sheet Highlights - Total current assets decreased to $1,705.1 million as of October 31, 2025, from $1,764.9 million in 2024[37]. - Cash and cash equivalents increased to $341.0 million as of October 31, 2025, compared to $199.5 million in 2024[37]. - The company’s total liabilities decreased to $1,985.5 million as of October 31, 2025, from $2,030.4 million in 2024[37]. - The effective tax rate for the twelve months ended October 31, 2025, was 16.3%, down from 18.3% in 2024[42]. - The company recorded a non-cash impairment charge of $81.1 million during the twelve months ended October 31, 2025[42].

[General Information](index=1&type=section&id=General%20Information) Provides foundational details about NeuroOne Medical Technologies Corporation, its incorporation, and registered securities - Registrant: **NeuroOne Medical Technologies Corporation**, incorporated in Delaware[2](index=2&type=chunk) Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, par value $0.001 per share | NMTC | The Nasdaq Stock Market LLC | - The registrant is not an emerging growth company[4](index=4&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Details the announcement of preliminary, unaudited financial results for the fiscal year ended September 30, 2025 - NeuroOne Medical Technologies Corporation announced preliminary, unaudited financial results for the fiscal year ended September 30, 2025, via a press release on October 6, 2025[5](index=5&type=chunk) - Information in this Item 2.02 and Exhibit 99.1 is furnished, not filed, and not incorporated by reference in Securities Act filings unless expressly stated[6](index=6&type=chunk) [Item 8.01 Other Events](index=2&type=section&id=Item%208.01%20Other%20Events) Covers additional significant events, including preliminary financial results for the fiscal year 2025 [Preliminary Results](index=2&type=section&id=Preliminary%20Results) For the fiscal year ended September 30, 2025, NeuroOne reported approximately $9.1 million in annual total product revenue and held approximately $6.6 million in cash and cash equivalents Preliminary Financial Highlights (FY2025) | Metric | Amount (approx.) | | :------------------------------------ | :--------------- | | Annual Total Product Revenue | $9.1 million | | Cash and Cash Equivalents (as of Sep 30, 2025) | $6.6 million | [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) Lists the exhibits filed with the Form 8-K, including a press release and interactive data file Exhibits Filed with Form 8-K | Exhibit No. | Description | | :---------- | :-------------------------------------------------- | | 99.1 | Press Release, dated October 6, 2025 | | 104 | Cover Page Interactive Data File (embedded with Inline XBRL document) | [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) Addresses cautionary information regarding future-oriented statements, their inherent uncertainties, and the company's disclosure obligations - This Current Report includes forward-looking statements concerning revenue, financial outlook, product demand, and growth expectations, based on current management expectations[8](index=8&type=chunk) - Preliminary, estimated financial results are unaudited, subject to final reviews and closing procedures, and may be materially inaccurate[8](index=8&type=chunk) - Actual future results may differ materially due to factors such as Nasdaq compliance, strategic partnerships, technology performance, capital needs, regulatory changes, and intellectual property rights; NeuroOne disclaims any obligation to update these statements[8](index=8&type=chunk) [Signatures](index=3&type=section&id=SIGNATURES) Confirms the official signing of the report by NeuroOne Medical Technologies Corporation's Chief Executive Officer - The report was signed on behalf of **NeuroOne Medical Technologies Corporation** by **David Rosa**, Chief Executive Officer, on October 6, 2025[12](index=12&type=chunk)

Financial Performance - Jabil reported net revenue of $8.3 billion for the first quarter of fiscal year 2026, a 19% increase from $6.994 billion in the same period last year[18]. - Core operating income (Non-GAAP) for the quarter was $454 million, with core diluted earnings per share (Non-GAAP) at $2.85, reflecting strong operational performance[6]. - The company raised its fiscal year 2026 outlook to a net revenue target of $32.4 billion, with a core operating margin (Non-GAAP) of 5.7% and core diluted earnings per share (Non-GAAP) of $11.55[5]. - For the second quarter of fiscal year 2026, Jabil expects net revenue between $7.5 billion and $8.0 billion, with core diluted earnings per share (Non-GAAP) projected to be between $2.27 and $2.67[4]. - Jabil's net income for the first quarter was $146 million, up from $100 million year-over-year, with diluted earnings per share increasing to $1.35 from $0.88[18]. - Net income for the three months ended November 30, 2025, was $146 million, compared to $100 million for the same period in 2024, representing a 46% increase[20]. - Operating income (U.S. GAAP) increased to $283 million in Q1 2025 from $197 million in Q1 2024, a growth of 43.6%[21]. - Core operating income (Non-GAAP) rose to $454 million, up from $347 million year-over-year, reflecting a 30.8% increase[21]. - Diluted earnings per share (U.S. GAAP) increased to $1.35 from $0.88, a growth of 53.4%[21]. Cash Flow and Assets - Adjusted free cash flow (Non-GAAP) is expected to exceed $1.3 billion for fiscal year 2026, supporting ongoing investments and shareholder returns[5]. - Jabil's total assets increased to $19.276 billion as of November 30, 2025, up from $18.543 billion at the end of the previous fiscal year[16]. - The company maintained strong free cash flow expectations while focusing on profitable growth and margin expansion[3]. - Adjusted free cash flow (Non-GAAP) for the three months ended November 30, 2025, was $272 million, compared to $226 million in the prior year, marking a 20.4% increase[23]. - Net cash provided by operating activities was $323 million, slightly up from $312 million in the same quarter last year[23]. - Cash and cash equivalents at the end of the period decreased to $1,572 million from $2,058 million year-over-year, a decline of 23.5%[20]. Restructuring and Charges - The company incurred $76 million in restructuring, severance, and related charges during the three months ended November 30, 2025[21]. - The company recorded $15 million in acquisition and divestiture-related charges during the three months ended November 30, 2025[21]. - The company reported a net cash used in financing activities of $503 million, compared to $312 million in the same period last year[20]. Growth Drivers - Jabil's Intelligent Infrastructure segment is a key growth driver, benefiting from increased demand in cloud, data center infrastructure, and networking[3].

Financial Performance - Fourth quarter revenue reached a record $2.3 billion, an increase of 5.4% year-over-year, with organic growth contributing 4.8%[4] - Net income for the quarter was $34.8 million, or $0.56 per diluted share, compared to a net loss of $(11.7) million, or $(0.19) per share in the prior year[7] - Adjusted EBITDA for the quarter was $124.2 million, with an adjusted EBITDA margin of 5.6%, compared to $125.6 million and 6.0% in the prior year[9] - Full year fiscal 2025 revenue was $8.7 billion, a 4.6% increase over the prior year, driven by 3.8% organic growth and 0.8% from acquisitions[12] - Revenues for the three months ended October 31, 2025, were $2,295.3 million, representing a 5.4% increase from $2,177.3 million in the same period of 2024[33] - For the fiscal year ended October 31, 2025, total revenues reached $8,745.9 million, up 4.6% from $8,359.4 million in 2024[34] - Total revenues for the three months ended October 31, 2025, increased by 5.4% to $2,295.3 million compared to $2,177.3 million in the same period of 2024[38] - For the fiscal year ended October 31, 2025, total revenues increased by 4.6% to $8,745.9 million from $8,359.4 million in 2024[39] Profitability - Operating profit for the same period was $68.4 million, a significant increase from $19.2 million in the prior year, indicating a notable improvement in operational efficiency[33] - The company reported an operating profit of $311.7 million for the fiscal year 2025, a 47.0% increase from $212.0 million in 2024[34] - Net income for the fiscal year 2025 was $162.4 million, a 99.6% increase from $81.4 million in 2024[39] - The segment operating margin for the three months ended October 31, 2025, improved to 8.2%, up from 7.9% in the same period of the previous year[38] - The company incurred $27.9 million in items impacting comparability for the three months ended October 31, 2025, compared to $77.5 million in the same period of 2024[41] Cash Flow and Investments - Net cash provided by operating activities for the three months ended October 31, 2025, was $133.4 million, significantly higher than $30.3 million in the same period of 2024[36] - Free cash flow for the three months ended October 31, 2025, reached $112.7 million, compared to $15.5 million in the same period of 2024[42] - Total cash used in investing activities for the fiscal year 2025 was $115.6 million, a decrease from $171.9 million in 2024, indicating a more conservative investment approach[36] - The company reported additions to property, plant, and equipment of $20.7 million for the three months ended October 31, 2025, up from $14.8 million in 2024[42] Shareholder Returns - The Board approved a 9% increase in the quarterly dividend to $0.29 per common share, marking the 58th consecutive year of annual dividend increases[19] - The company declared dividends of $0.265 per common share for the three months ended October 31, 2025, compared to $0.225 in the same period of 2024[33] - The company repurchased $73.0 million of common stock in the fourth quarter and $121.3 million for the full year, reducing outstanding shares by 4%[4] Debt and Liquidity - The company ended the quarter with total indebtedness of $1.6 billion and a leverage ratio of 2.7x, with available liquidity of $681.6 million[17] - Current liabilities decreased to $1,305.7 million in 2025 from $1,348.4 million in 2024, reflecting improved financial management[37] - Interest expense for the fiscal year 2025 was $96.4 million, up from $85.0 million in 2024, reflecting increased borrowing costs[34] Future Outlook - For fiscal 2026, adjusted EPS is projected to be in the range of $3.85 to $4.15, excluding any potential prior year self-insurance adjustments[20] - Organic revenue growth for fiscal 2026 is expected to be between 3% to 4%, with an additional point of growth anticipated from the WGNSTAR acquisition[20] Operational Efficiency - The company incurred costs associated with restructuring programs aimed at improving operational efficiency[44] - Discrete transformational costs for developing technological needs amounted to significant investments in new systems and tools[45] - The company revised its non-GAAP financial measures to include prior year self-insurance adjustments for better comparability[43] Taxation - The tax impact for FY2025 was calculated using a federal and state statutory rate of 27.72%[47]

Financial Performance - Net sales for the second quarter were $4.9 billion, down 7%, with organic net sales down 1%[5] - Operating profit decreased by 32% to $728 million, while adjusted operating profit was down 20% in constant currency to $848 million[6] - Diluted earnings per share (EPS) fell 45% to $0.78, with adjusted diluted EPS down 21% in constant currency to $1.10[5] - For the quarter ended November 23, 2025, net sales were $4,860.8 million, a decrease of 7% compared to $5,240.1 million in the same quarter of 2024[32] - Operating profit for the same quarter was $728.0 million, down 32% from $1,077.9 million year-over-year[32] - Net earnings attributable to General Mills for the quarter ended Nov. 23, 2025, were $413.0 million, or 8.5% of net sales, compared to $795.7 million and 15.2% in the same quarter of 2024[74] - Adjusted net earnings attributable to General Mills for the six-month period ended Nov. 23, 2025, were $1,059.6 million, or 11.3% of net sales, compared to $1,391.1 million and 13.8% in the prior year[76] - The total segment operating profit for the six-month period ended Nov. 23, 2025, decreased by 17% on a reported basis[80] Sales by Segment - North America Retail segment net sales decreased 13% to $2.9 billion, with organic net sales down 3%[12] - North America Pet segment net sales increased 11% to $660 million, benefiting from the North American Whitebridge Pet Brands acquisition[14] - International segment net sales rose 6% to $729 million, with organic net sales up 4%[19] - North America Retail segment net sales decreased by 13% to $2,883.3 million for the quarter ended November 23, 2025[35] - The International segment reported a 6% increase in net sales to $728.9 million for the same quarter[35] - The North America Pet segment saw an 11% increase in net sales, reaching $660.4 million for the quarter[35] Future Expectations - The company expects a 25% increase in sales from new products in fiscal 2026, driven by investments in brand remarkability[3] - General Mills expects organic net sales growth to range between down 1% and up 1% for fiscal 2026[30] - Adjusted operating profit and adjusted diluted EPS are projected to decline by 10% to 15% in constant currency[30] - The company anticipates a net impact of divestitures and acquisitions to reduce full-year net sales growth by approximately 4%[30] - The company expects to incur approximately $82 million of restructuring charges related to a multi-year organizational initiative to enhance supply chain competitiveness[45] - The company expects a net sales growth reduction of approximately 4% due to foreign currency exchange rates, acquisitions, and a 53rd week in fiscal 2026[55] - Restructuring and transformation charges for fiscal 2026 are expected to total approximately $160 million to $165 million[55] Cash Flow and Assets - Cash provided by operating activities totaled $1.2 billion through six months, down from $1.8 billion a year ago[25] - Cash and cash equivalents at the end of the period were $683.4 million, down from $2,292.8 million at the end of the previous year[40] - The net cash provided by operating activities was $1,216.3 million for the six-month period ended November 23, 2025, compared to $1,774.7 million in the same period last year[41] - Total current assets decreased to $5,071.1 million as of November 23, 2025, from $7,381.4 million a year earlier[38] - Total liabilities decreased to $23,220.2 million as of November 23, 2025, compared to $23,946.9 million in the previous year[38] Restructuring and Charges - Restructuring and other exit costs totaled $122 million in the second quarter, significantly higher than $1 million a year ago[23] - Restructuring, transformation, and impairment charges totaled $125.1 million for the six-month period ended November 23, 2025[46] - The company recorded a $53 million non-cash impairment charge related to the Uncle Toby's brand intangible asset in the second quarter of fiscal 2026[46] - Restructuring and transformation charges for the quarter ended Nov. 23, 2025, amounted to $72.2 million, contributing 1.5% to operating profit[74] Tax and Earnings - The effective tax rate for the second quarter was 23.3%, compared to 20.1% last year[24] - The effective tax rate for the six-month period ended November 23, 2025, was 24.9%, an increase of 4.0 percentage points from 20.9% in the same period last year[50] - Diluted earnings per share for the six-month period ended November 23, 2025, were $3.00, a 22% increase from $2.45 in the same period last year[71] - Unallocated corporate expense totaled $214 million for the six-month period ended November 23, 2025, up from $189 million in the same period last year[49] Acquisitions and Divestitures - The company recorded a pre-tax gain of $1,046 million from the sale of its United States yogurt business to Groupe Lactalis S.A. in the first quarter of fiscal 2026[47] - The acquisition of NX Pet Holding, Inc. for $1 billion resulted in goodwill of $1,087 million and an indefinite-lived intangible asset for the Tiki Pets brand totaling $289 million[44] - The company recorded $14 million in transaction costs related to the sale of its United States yogurt business in the six-month period ended November 23, 2025[49] - The company experienced a divestiture gain of $1,054.4 million, which negatively impacted the operating profit margin by 11.2% for the six-month period ended Nov. 23, 2025[76]

Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress — Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA — — Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and bo ...

Market Opportunities - The epilepsy market presents a significant opportunity, with approximately 3,000,000 patients in the U.S. and an estimated annual cost of $15.5 billion[30] - The chronic back pain market, particularly through spinal cord stimulation (SCS), is valued at approximately $2.5 to $3 billion globally[36] - The total market for Basivertebral Nerve Ablation (BVNA) procedures in the U.S. is estimated at around $100 million per year, with over 10,000 procedures performed annually[40] - The Parkinson's disease market includes around 1,000,000 patients in the U.S., with 60,000 new diagnoses each year, highlighting a significant treatment need[42] - The company is developing a drug delivery system that has already been ordered by a large biopharmaceutical company, representing a new market opportunity exceeding $50 million[41] Product Development and Regulatory Approvals - The company has received 510(k) clearance for four devices, including the Evo Cortical and OneRF Brain Ablation System, enhancing its product portfolio for brain-related conditions[23] - The OneRF TN Ablation System features a "first-of-its-kind" multi-contact RF probe, potentially reducing procedural time and improving patient safety[25] - The company is pursuing FDA clearance for a new drug delivery device intended for neurological therapies, which could expand its market reach significantly[27] - The company is pursuing a 510(k) clearance with the FDA for its drug delivery system and BVNA product[54] - Four products have received 510(k) clearance from the FDA: Evo Cortical, Evo sEEG, OneRF Ablation System, and OneRF TN Ablation System, while other products are still under development[173] Financial Performance and Funding - In fiscal 2025, the company generated approximately $9.1 million in product revenue from the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System[50] - The company raised approximately $8.2 million from the sale of 16 million shares at $0.50 per share in April 2025[70] - As of September 30, 2025, the company had an accumulated deficit of $78.6 million, primarily due to expenses from operations and research and development programs[144] - The company has incurred significant operating losses since inception and does not expect to achieve profitability in the foreseeable future[145] - The company had cash and cash equivalents of approximately $6.6 million as of September 30, 2025, which is insufficient to fund ongoing operating expenses[156] Competition and Market Dynamics - The company faces competition in the epilepsy diagnosis market from Ad-Tech Medical Instrument Corporation, PMT Corporation, and Dixi Medical, among others[84] - The market for trigeminal neuralgia treatment includes competition from Boston Scientific and Avanos RF ablation systems[87] - The company faces significant competition from established players in the medical device industry, which may impact market acceptance[212] - Competitors may have advantages such as more experienced sales forces, greater name recognition, and established distribution networks[215] - The company may face challenges in developing and commercializing new products due to competition and market dynamics[214] Regulatory Compliance and Risks - The company is subject to extensive governmental regulation, and failure to comply could adversely affect its business[146] - The FDA classifies medical devices into three classes (I, II, III) based on risk, with Class III requiring the most regulatory control and typically a Premarket Approval (PMA) process[108] - Non-compliance with regulatory requirements can lead to significant consequences, including product recalls, fines, and potential criminal prosecution[128] - The PMA approval process can be lengthy and costly, with many devices never receiving approval despite applications being submitted[120] - Regulatory compliance and scrutiny will continue to be a significant responsibility for the company, even after obtaining product approvals[181] Research and Development - Research and development expenses for the years ended September 30, 2025, and 2024 were $5.0 million and $5.1 million, respectively, indicating a slight decrease[82] - The company is focused on developing comprehensive neuromodulation solutions for neurological disorders, including epilepsy and Parkinson's disease[148] - Clinical testing for new products is expensive and time-consuming, with potential delays impacting the ability to generate revenue[174] - The company may need to conduct additional clinical trials or testing, which could delay marketing approval for its technologies[177] - The company is exploring partnerships for drug delivery systems capable of therapy delivery and monitoring for up to 30 days[50] Intellectual Property and Partnerships - The patent estate includes multiple issued patents and pending applications, with expiration dates ranging from 2028 to 2045, highlighting the importance of intellectual property protection[94] - The partnership with Mayo is crucial for licensing know-how for the development and commercialization of technology, and its termination would harm the business[221] - The Mayo Development Agreement includes exclusive licensing of certain improvements and non-exclusive licensing of thin film electrode technology know-how[221] Operational Challenges - The company relies on reimbursement from private third-party healthcare payors and Medicare, which is critical for its success, but future coverage levels are uncertain[74] - The company relies on a limited number of third-party suppliers for components, which exposes it to risks related to pricing, availability, and quality[168] - The inability to obtain a supply of components and raw materials could materially adversely affect the company's business and financial condition[163] - The company faces fierce competition in recruiting and retaining qualified personnel, which could harm business if competitors are more successful[216] - The company has faced substantial doubt about its ability to continue as a going concern due to ongoing losses and negative cash flows from operations[156]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2025. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-10843 CSP Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 04-2441294 (State or other jurisdiction of ...